ArticleBMC cancer2026
Fusion of MRI-radiomics and clinical features to improve pathological T-stage prediction of rectal cancer: a multicenter study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundDeveloping a rational model for precise preoperative staging of rectal cancer using magnetic resonance imaging is crucial for improving the therapeutic effect and prognosis of patients. To investigate the feasibility and efficacy of a T2-weighted imaging (T2WI) based radiomics model combined with clinical features for preoperative T1-2/T3 staging prediction in rectal cancer.
methodsA total of 968 rectal adenocarcinoma patients (T1-2 stage, n = 562; T3 stage, n = 406) were retrospectively enrolled in this study. We randomly divided it into a training cohort (n = 774) and an internal validation cohort (n = 194). Additional 82 patients from another center used as an independent external validation cohort. For each patient, 1210 radiomics features were extracted from T2WI images. Least absolute shrinkage and selection operator were applied for feature selection. Support vector machine classifier was used to develop the radiomics model. Six clinical features were collected and selected to build the clinical model using the recursive feature elimination algorithm. A weighted fusion method was applied to combine the radiomics with clinical model to develop the fusion model. The performances of the above three models were evaluated using ROC, calibration, and decision curves.
resultsThe radiomics and clinical model yielded AUC of 0.858 (95% CI, 0.801-0.904) and 0.780 (95% CI, 0.715-0.836) in internal validation cohort, while the fusion model generated higher performance with AUC of 0.875 (95% CI, 0.820-0.918). The external validation cohort further validated the effectiveness of the fusion model with AUC of 0.828 (95% CI, 0.729-0.903). The calibration and decision curves confirmed that the fusion model was well calibrated and had clinical utility.
conclusionsCombined T2WI radiomics features and clinical features modeling can effectively predict T-stage (T1-2/T3) of rectal cancer and provide valuable reference for clinical decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.